A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 4, 2019

Primary Completion Date

November 8, 2021

Study Completion Date

September 30, 2026

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Mobocertinib

Mobocertinib capsule.

Trial Locations (25)

Unknown

Aichi Cancer Center Hospital, Nagoya

Fujita Health University Hospital, Toyoake

National Cancer Center Hospital East, Kashiwa

Kurume University Hospital, Kurume

Hokkaido Cancer Center, Sapporo

Hyogo Cancer Cente, Akashi

Kanazawa University Hospital, Kanazawa

Kanagawa Cancer Center, Yokohama

Sendai Kousei Hospital, Sendai

Okayama University Hospital, Kita-ku

Kansai Medical University Hospital, Hirakata

National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai

Kindai University Hospital, Sayama

Saitama Cancer Center, Shinden

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku

National Cancer Center Hospital, Chuo-ku

Cancer Institute Hospital, Koto-ku

Yamaguchi Ube Medical Center, Ube

Kyushu University Hospital, Fukuoka

Hiroshima University Hospital, Hiroshima

Kyoto University Hospital, Kyoto

Niigata Cancer Center Hospital, Niigata

Osaka International Cancer Institute, Osaka

Tokushima University Hospital, Tokushima

Wakayama Medical University Hospital, Wakayama

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY